SCHEMBL1921365

SCHEMBL1921365

CN1Cc2nc(N3CCSCC3)ncc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
HPGD P15428 2/20 0.38
USP2 O75604 3/20 0.37
MAPT P10636 2/20 0.37
PTPN11 Q06124 2/20 0.37
HTT P42858 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 3/20 0.35
CYP1A2 P05177 3/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
LMNA P02545 3/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 2/20 0.33
HTR2A P28223 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1845428 0.86 USP2 (0.44) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
SCHEMBL4142203 0.86 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
SCHEMBL1849473 0.83 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HPGDUSP2HSD17B10
SCHEMBL1846180 0.83 ALDH1A1 (0.57) ALDH1A1USP2HSD17B10CYP1A2CASP1
SCHEMBL1923248 0.82 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
SCHEMBL4767494 0.81 TSHR (0.47) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
SCHEMBL1921107 0.79 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
Maleic Acid SCHEMBL29413890 0.77 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
SCHEMBL8898023 0.75 HTT (0.64) ALDH1A1SMN1; SMN2HPGDUSP2MAPT
Maleic Acid SCHEMBL2874748 0.75 HSD17B10 (0.41) ALDH1A1SMN1; SMN2HPGDUSP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US claimed
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS Progenicyte Therapeutics, Inc. (US) 2023-09-28 US disclosed
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2021-02-18 US disclosed
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2020-08-06 US disclosed
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2019-06-06 US disclosed
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2018-04-05 US disclosed
EP-2326330-B1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIV CENTRAL FLORIDA RES FOUND (US) 2015-01-07 EP disclosed
US-8791128-B2 Compositions for treating or delaying the onset of hair loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-07-29 US disclosed
US-20110190320-A1 Compositions for Treating or Delaying the Onset of Hair Loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2011-08-04 US disclosed
EP-2326330-A1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS University Of Central Florida Research Foundation, Inc. (US) 2011-06-01 EP disclosed
WO-2010033576-A1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-03-25 WO disclosed
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TREMBLEY MARCELLA 2009-04-02 US disclosed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US disclosed
EP-1890673-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSMIP Assets B.V. (NL) 2008-02-27 EP disclosed
WO-2006133876-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSM IP ASSETS B.V. (NL) 2006-12-21 WO disclosed
US-5976523-A PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES MITSUI PHARMACEUTICALS, INC. (JP) 1999-11-02 US disclosed
EP-0743066-A2 Wound-healing agent MITSUI PHARMACEUTICALS, INC. (JP) 1996-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885SMN1; SMN2 205/4885HPGD 1542/4885
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885SMN1; SMN2 205/4885HPGD 1542/4885
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS PSEN1, PSEN2, NES ALDH1A1 4397/4885SMN1; SMN2 80/4885HPGD 1162/4885
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TYMP, TYMS, UNG ALDH1A1 1067/4885SMN1; SMN2 3270/4885HPGD 185/4885
US-20110190320-A1 Compositions for Treating or Delaying the Onset of Hair Loss SHBG, CYP19A1, TYMP ALDH1A1 1649/4885SMN1; SMN2 4808/4885HPGD 385/4885
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885SMN1; SMN2 205/4885HPGD 1542/4885
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS NES, PSEN1, PSEN2 ALDH1A1 2409/4885SMN1; SMN2 78/4885HPGD 1327/4885
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885SMN1; SMN2 205/4885HPGD 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.